Ultimately, Medtronic’s global IN.PACT clinical program will include 24 studies involving approximately 4,000 patients and 200 sites across more than 80 countries worldwide. Through these company-sponsored and physician-initiated studies, Medtronic IN.PACT drug-eluting balloons will be investigated thoroughly for the treatment of arterial disease in coronary and peripheral vessel beds.Last month, for example, Medtronic announced the start of the IN.PACT Global SFA clinical study, an international research program to evaluate the treatment of peripheral artery disease using the company’s IN.PACT Admiral ™ drug-eluting balloon in up to 1,500 “real world” patients. The first patient in the study is expected to be enrolled by the end of May.
CORRECTING And REPLACING Medtronic IN.PACT Drug-Eluting Balloon Studies Show Significant Benefit Of Novel Medical Device In Treating Narrowed Arteries
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.